Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We use our state-of-the-art dedicated workflow for designing focused libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

This includes comprehensive molecular simulations of the receptor in its native membrane environment, paired with ensemble virtual screening that factors in its conformational mobility. In cases involving dimeric or oligomeric receptors, the entire functional complex is modelled, pinpointing potential binding pockets on and between the subunits to capture the full range of mechanisms of action.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P11473

UPID:
VDR_HUMAN

ALTERNATIVE NAMES:
1,25-dihydroxyvitamin D3 receptor; Nuclear receptor subfamily 1 group I member 1

ALTERNATIVE UPACC:
P11473; B2R5Q1; G3V1V9; Q5PSV3

BACKGROUND:
The Vitamin D3 receptor, identified by its engagement with calcitriol, the active form of vitamin D3, and its alternative names, 1,25-dihydroxyvitamin D3 receptor and Nuclear receptor subfamily 1 group I member 1, is essential for calcium homeostasis and vitamin D3's biological actions. It operates by binding to vitamin D3, translocating to the nucleus, and partnering with the retinoid X receptor to initiate the transcription of vitamin D3-responsive genes.

THERAPEUTIC SIGNIFICANCE:
Critical in the pathogenesis of Rickets vitamin D-dependent 2A, the Vitamin D3 receptor's dysfunction leads to severe rickets and hypocalcemia. Targeting the Vitamin D3 receptor offers a promising avenue for developing treatments for diseases caused by its variants, highlighting its therapeutic significance.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.